The Alzheimer’s disease drug development landscape

Hosted by: Julius Clinical.Speakers:Pieter van Bokhoven | CSO| IAO Amsterdam Neuroscience AUMC Jort Vijverberg | Neurologist | Amsterdam Neuroscience AUMCTopics that are discussed during this webinar:All major trends in Alzh...

Speakers: Dr. Jort Vijverberg
  • Webinars
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Public health and policy responses to NAFLD/NASH

Topics that has been discussed:The Impact of NAFLD/NASH What is being done to tackle NAFLD/NASH globally and nationally What still needs to be done in the fight against NAFLD/NASH How can you/your country advance the battle against ...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.
  • Webinars
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Genetic architecture of NAFLD: where do we stand?

Genome-wide association studies have uncovered robust and reproducible associations between several genetic variations and the natural history of NAFLD. During this webinar, Professor Eric Trépo reviewed these findings that have provided compelli...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.
  • Webinars
  • Infectious Diseases & Vaccines, Vaccines

COVID-19 lessons from pandemic to endemic

We presented the webinar COVID-19 lessons from pandemic to endemic. During this webinar Prof. Jerome H. Kim, Director General of the International Vaccine Institute (IVI), discussed:- Pandemic preparedness – lessons learned - Clinical Devel...

Speakers: Leyla Kragten-Tabatabaie
  • Webinars
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Promising phase 2B trial results of Lanifibranor in NASH

During this webinar Prof. Sven Francque discussed the phase 2 trial results of the Pan-PPAR Agonist Lanifibranor in nonalcoholic steatohepatitis (NASH) patients. Currently there is an unmet need of management of NASH. Lanifibranor is a pan-PPAR (p...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.
  • Webinars
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Insulin Resistance in NAFLD

This webinar focussed on the close multilevel links between insulin resistance/T2DM and NAFLD.Topics that are discussed:Epidemiological links between NAFLD, insulin resistance and T2DM Insulin resistance as root cause of NAFLD: mechan...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

Innovative Endpoints in Alzheimer’s Disease Clinical Trials

Together with our partner Brain Research Center, we presented the webinar: Innovative Endpoints in Alzheimer’s Disease Clinical trials.During this webinar, two experts in the field, Dr. Niels Prins and Dr. Jort Vijverberg discussed the ...

Speakers: Dr. Jort Vijverberg
  • Webinars
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Non-invasive diagnosis and disease staging of NAFLD

Given the high prevalence of NAFLD in the general population, identifying the persons at a high risk for development of cirrhosis is key. During this presentation, Professor Hannes Hagström focussed on methods and strategies to achieve this in di...

Speakers: Prof. Manuel Castro Cabezas - Prof. dr. Christophe Moreno, M.D.

Download

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn